Are you sure?

Roche's NeoRecormon wins European approval for weekly use

Roche Holding AG, the world's biggest maker of cancer drugs, won European regulatory approval to sell its NeoRecormon medicine as a weekly injection to treat anemia in cancer patients undergoing chemotherapy.

NeoRecormon is already sold in a version that requires three injections a week, the Basel, Switzerland-based company said in an e-mailed statement. Anemia affects as many as 95% of cancer patients receiving chemotherapy, Roche Holding AG said. „This expansion of the product label means that patients will no longer have the burden of three injections per week and their anemia can be managed in a more convenient way,” Roche said in the statement today. (Bloomberg)